Skip to main content
Fig. 5 | Journal of Nanobiotechnology

Fig. 5

From: pH-responsive delivery vehicle based on RGD-modified polydopamine-paclitaxel-loaded poly (3-hydroxybutyrate-co-3-hydroxyvalerate) nanoparticles for targeted therapy in hepatocellular carcinoma

Fig. 5

a The stability of nanoparticles in PBS solution (mean ± SD, n = 3). b Hemolysis rate of different nanoparticles in vitro (mean ± SD, n = 3). c Effects of different nanoparticles on hemolysis in vitro. d Cytotoxicity against L02 cells after incubation with different concentrations of RGD-PDA-PHBV-NPs (PTX-free) for 48 h. In vitro drug release profile of PHBV-PTX-NPs (e), PDA-PHBV-PTX-NPs (f), RGD-PDA-PHBV-PTX-NPs (g) and raw PTX (h) in PBS with different pH value (n = 3). One way ANOVA, *p < 0.05; **p < 0.01, ***p < 0.001. PHBV, ploy (3-hydroxybutyrate-co-3-hydroxyvalerate); PTX, paclitaxel; PDA, polydopamine; NPs, nanoparticles

Back to article page